Site-specific Risk Stratification Models for Postoperative Recurrence and Survival Prediction in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: Better Stratification for Adjuvant Therapy

[1]  J. Witjes,et al.  Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. , 2021, The New England journal of medicine.

[2]  M. Miyake,et al.  Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma , 2020, Cancers.

[3]  Steven L. Chang,et al.  Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. , 2020, European urology.

[4]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.

[5]  T. Shimokama,et al.  A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables , 2020, International Journal of Clinical Oncology.

[6]  J. Donovan,et al.  Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial , 2020, The Lancet.

[7]  H. Matsuyama,et al.  Down-Grading of Ipsilateral Hydronephrosis by Neoadjuvant Chemotherapy Correlates with Favorable Oncological Outcomes in Patients Undergoing Radical Nephroureterectomy for Ureteral Carcinoma , 2019, Diagnostics.

[8]  B. Song,et al.  Patients’ self-report anxiety, depression and quality of life and their predictive factors in muscle invasive bladder cancer patients receiving adjuvant chemotherapy , 2019, Psychology, health & medicine.

[9]  S. Shariat,et al.  Risk stratification of upper tract urothelial carcinoma: A Review of the Current Literature , 2019, Expert review of anticancer therapy.

[10]  K. Shimada,et al.  Preoperative predictive factors focused on inflammation-, nutrition-, and muscle-status in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy , 2019, International Journal of Clinical Oncology.

[11]  H. Shiina,et al.  Risk stratification by means of biological age-related factors better predicts cancer-specific survival than chronological age in patients with upper tract urothelial carcinoma: a multi-institutional database study , 2018, Therapeutic Advances in Urology.

[12]  H. Shiina,et al.  Biological Behavior and Long‐Term Outcomes of Carcinoma In Situ in Upper Urinary Tract Managed by Radical Nephroureterectomy , 2017, The Journal of urology.

[13]  S. Shariat,et al.  Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review , 2017, World Journal of Urology.

[14]  H. Shiina,et al.  Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma treated in the last two decades: a retrospective analysis based on a multicenter collaborative study. , 2016, Japanese journal of clinical oncology.

[15]  David A. Green,et al.  Urothelial carcinoma of the bladder and the upper tract: disparate twins. , 2013, The Journal of urology.

[16]  J. Catto,et al.  Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours , 2013, World Journal of Urology.

[17]  K. Bennett,et al.  Opt-out as an acceptable method of obtaining consent in medical research: a short report , 2011, BMC medical research methodology.

[18]  F. Ito,et al.  Template‐based lymphadenectomy in urothelial carcinoma of the upper urinary tract: Impact on patient survival , 2010, International journal of urology : official journal of the Japanese Urological Association.

[19]  K. Bensalah,et al.  Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. , 2010, European urology.

[20]  L. Martínez-Piñeiro,et al.  Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.

[21]  M. Milowsky,et al.  Surveillance of urothelial carcinoma , 2009, Cancer.

[22]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.

[23]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[24]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[25]  T. Styš.  An extension of the maximum principle , 1988 .